Literature DB >> 9830466

Radiation proctitis. Clinical and pathological manifestations, therapy and prophylaxis of acute and late injurious effects of radiation on the rectal mucosa.

F B Zimmermann1, H J Feldmann.   

Abstract

BACKGROUND: Often the rectum is the dose-limiting organ in curative radiation therapy of pelvic malignancies. It reacts with serous, mucoid, or more rarely bloody diarrhea.
METHODS: A research for reports on prophylactic and supportive therapies of radiation-induced proctitis was performed (Medline, Cancerlit, and others).
RESULTS: No proven effective prophylactic local or systemic therapies of radiation proctitis exist. Also, no reasonable causal medication is known. In the treatment of late radiation sequelae no clinically tested certain effective therapy exists, too. Antiinflammatory, steroidal or non-steroidal therapeutics as well as sucralfate can be used as topical measures. They will be successful in some patients. Side effects are rare and the therapy is cost-effective. Treatment failures can be treated by hyperbaric oxygen. This will achieve good clinical results in about 50% of the cases. Single or few mucosal telangiectasias with rectal bleeding can be treated sufficiently by endoscopic catheterization.
CONCLUSION: Besides clinical studies acute proctitis should be treated just symptomatically. Radical surgery should be performed only when all conventional treatments have been uneffective, although no certain effective therapies of radiation-induced late proctitis exist.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9830466

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  7 in total

1.  Protective effect of mesalamine against oxidativeinjury in a rat model of radiation rectitis.

Authors:  Neşe Kiremit-Korkut; Cağatay Korkut; Hatice Bilge
Journal:  Curr Ther Res Clin Exp       Date:  2004-09

2.  Histopathological comparison of topical therapy modalities for acute radiation proctitis in an experimental rat model.

Authors:  Cagatay Korkut; Oktar Asoglu; Murat Aksoy; Yersu Kapran; Hatice Bilge; Nese Kiremit-Korkut; Mesut Parlak
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

3.  Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.

Authors:  Konstantinos H Katsanos; Evangelos Briasoulis; Pericles Tsekeris; Anna Batistatou; Maria Bai; Christos Tolis; Antonio Capizzello; Ioannis Panelos; Vasileios Karavasilis; Dimitrios Christodoulou; Epameinondas V Tsianos
Journal:  J Exp Clin Cancer Res       Date:  2010-06-10

4.  Recent advances in the management of radiation colitis.

Authors:  Jannis Kountouras; Christos Zavos
Journal:  World J Gastroenterol       Date:  2008-12-28       Impact factor: 5.742

5.  Grading acute radiation bowel injury an unaddressed issue.

Authors:  Konstantinos H Katsanos; Dimitrios E Sigounas; Dimitrios K Christodoulou; Epameinondas V Tsianos
Journal:  Ann Gastroenterol       Date:  2012

6.  PPARs in Irradiation-Induced Gastrointestinal Toxicity.

Authors:  Christine Linard; Maâmar Souidi
Journal:  PPAR Res       Date:  2009-11-22       Impact factor: 4.964

Review 7.  Cytoprotective efficacy of amifostine against radiation- induced rectal toxicity: objective and subjective grading scales for radiomucositis.

Authors:  Vassilis E Kouloulias; John R Kouvaris
Journal:  Molecules       Date:  2008-04-18       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.